CAJ | 학술논문

　　目的?评价吉西他滨联合长春瑞滨二线治疗晚期鼻咽癌的近期疗效和毒性反应。方法?38例均为含顺铂方案一线化疗失败的晚期鼻咽癌患者，接受吉西他滨联合长春瑞滨方案治疗，吉西他滨1000mg/m2静脉滴注30min，d1、d8，长春瑞滨25mg/m2静脉推注，d1、d8，每21d重复一次。结果?38例共完成167个周期的治疗，中位数4周期，范围2~6周期，均可评价疗效，其中CR5例，PR20例，SD9例， PD4例，客观有效率(CR+PR)65.8%，中位缓解时间5.6个月。中位疾病进展时间6.2个月，中位生存期16.2个月；1年生存率65.8%，2年生存率44.7%。不良反应主要为Ⅰ~Ⅱ度骨髓抑制、末梢神经毒性及胃肠道反应。结论?吉西他滨联合长春瑞滨二线治疗转移性鼻咽癌患者，初步观察疗效可，毒副作用可耐受，值得临床进一步研究。
　　목적?평개길서타빈연합장춘서빈이선치료만기비인암적근기료효화독성반응。방법?38례균위함순박방안일선화료실패적만기비인암환자，접수길서타빈연합장춘서빈방안치료，길서타빈1000mg/m2정맥적주30min，d1、d8，장춘서빈25mg/m2정맥추주，d1、d8，매21d중복일차。결과?38례공완성167개주기적치료，중위수4주기，범위2~6주기，균가평개료효，기중CR5례，PR20례，SD9례， PD4례，객관유효솔(CR+PR)65.8%，중위완해시간5.6개월。중위질병진전시간6.2개월，중위생존기16.2개월；1년생존솔65.8%，2년생존솔44.7%。불량반응주요위Ⅰ~Ⅱ도골수억제、말소신경독성급위장도반응。결론?길서타빈연합장춘서빈이선치료전이성비인암환자，초보관찰료효가，독부작용가내수，치득림상진일보연구。
Objective?To?evaluate?gemcitabine?plus?vinorelbine?second-line?treatment?of?metastatic?nasopharyngeal?efficacy?and?toxicity.?Method?38?cases?are?cisplatin-containing?ifrst-line?chemotherapy?failure?in?patients?with?metastatic?nasopharyngeal,?receiving?gemcitabine?plus?vinorelbine?regimen,?gemcitabine?1000?mg/m2?intravenously?30?min,?d1,?d8,?vinorelbine?25mg/m2?intravenous?bolus?d1,?d8,?repeated?every?21?days?time.?Results?38?patients?completed?167?cycles?of?treatment,?with?a?median?4?cycles,?range?2-6?cycles,?can?be?evaluated,?CR5?cases,?the?PR20?cases,?SD9?patients,?PD4?patients,?the?objective?response?rate?(CR+PR)?65.8%.?The?median?duration?of?5.6?months.?The?median?time?to?progression?was?6.2?months,?with?a?median?survival?time?of?16.2?months;?1?year?survival?rate?was?65.8%,?2?year?survival?rate?was?44.7%.?The?main?adverse?reactions?of?Ⅰ-Ⅱ?degree?of?bone?marrow?suppression,?peripheral?neurotoxicity?and?gastrointestinal?reactions.?Conclusion?Vinorelbine,?gemcitabine?combined?with?second-line?treatment?of?metastatic?nasopharyngeal?carcinoma?patients,?preliminary?observations?have?a?certain?effect,?toxicity?is?tolerated,?is?worthy?of?further?study.